Call for Manuscript Submissions for a Thematic eJIFCC Issue on "Pharmacogenetics and Personalized Therapy" [0.03%]
面向精准治疗的药物基因组学专题征稿通知
Ron H N van Schaik,Sanja Stankovic
Ron H N van Schaik
Kinetics of Antibody Response to Repeated Vaccination with Sputnik V: A Pilot Study with a Series of Five Cases [0.03%]
卫星五号疫苗重复接种的抗体动力学：五例系列研究报告
Aleksandra Atanasova Boshku,Vasko Aleksovski,Gligor Tofoski et al.
Aleksandra Atanasova Boshku et al.
Objectives: Widespread vaccination is considered as one of the best methods in combating any pandemic including COVID-19. Gam-COVID-Vac also known as Sputnik V, is one of the first vaccines that was registered in 74 count...
Utility of Biochemical Markers in Predicting Severe COVID-19: Experience from a Tertiary Hospital in South India [0.03%]
生化标志物预测印度南部三级医疗机构COVID-19重症化的价值：单中心经验教训
Mamatha T Shenoy,Pradipta Kumar Mohanty,K Suganthy et al.
Mamatha T Shenoy et al.
Background: Coronavirus Disease 2019 (COVID-19) patients can present with a wide array of symptoms. For laboratory investigation of these patients several biochemical tests are routinely requested. Here we wanted to evalu...
Prognostic Value of Routine Blood Parameters in Intensive Care Unit COVID-19 Patients [0.03%]
重症监护室COVID-19患者常规血液检测参数的预后价值
Nada Yousfi,Ines Fathallah,Amal Attoini et al.
Nada Yousfi et al.
Introduction: Laboratory medicine has an important role in the management of COVID-19. The aim of this study was to analyze routinely available blood parameters in intensive care unit COVID-19 patients and to evaluate the...
Newly Diagnosed Chronic Lymphocytic Leukemia During Symptomatic COVID-19: Two Cases [0.03%]
两名COVID-19症状患者新诊断出慢性淋巴细胞白血病病例报告
Enikő Papp,Szabolcs Tasnády,Katalin Tisza et al.
Enikő Papp et al.
Patients suffering from malignant diseases have a high risk of developing severe or critical forms of COVID-19 (Coronavirus Disease 2019). Chronic lymphocytic leukaemia (CLL) is characterized by dysregulated adaptive and innate immune respo...
Béla Nagy Jr
Béla Nagy Jr
Editorial
EJIFCC. 2022 Aug 8;33(2):75-78. DOI: 2022
Performance of Elecsys Anti-SARS CoV-2 (Roche) and VIDAS Anti-SARS CoV-2 (Biomérieux) for SARS-CoV-2 Nucleocapsid and Spike Protein Antibody Detection [0.03%]
罗氏和生物梅里埃SARS-CoV-2核衣壳和刺突蛋白抗体检测的性能评估：流行病学调查的研究报告
Riberi María Inés,Hernandez Toledo Marina Gabriela,Cid Mariana Paula et al.
Riberi María Inés et al.
Introduction: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the novel viral pathogen that causes coronavirus disease 2019 (COVID-19) in humans, has spread worldwide since its identification in late 2019. T...
Review
EJIFCC. 2022 Aug 8;33(2):159-165. DOI: 2022
Laboratory Considerations for Reporting Cycle Threshold Value in COVID-19 [0.03%]
报告新型冠状病毒肺炎循环阈值的实验室考虑因素
Rivak Punchoo,Sachin Bhoora,Avania Bangalee
Rivak Punchoo
The Coronavirus Disease 2019 (COVID-19) pandemic is caused by the SARS-CoV-2 RNA virus. Nucleic acid amplification testing (NAAT) is the mainstay to confirm infection. A large number of reverse transcriptase polymerase chain reaction (RT-PC...
Review
EJIFCC. 2022 Aug 8;33(2):80-93. DOI: 2022
Verification and Comparison of Qualitative Serological Assays for Anti-SARS-COV-2 IgM and IgG Antibodies Detection [0.03%]
用于检测抗SARS-CoV-2 IgM和IgG抗体的定性血清学检测试剂盒的验证与比较研究
Maša Štebih,Milan Skitek,Aleš Jerin
Maša Štebih
Background: Due to their wide application in the SARS-CoV-2 pandemic, we verified and compared three qualitative serological methods in order to select the most optimal that will best serve its purpose under laboratory co...
Review
EJIFCC. 2022 Aug 8;33(2):145-158. DOI: 2022
Systematic Review of Diagnostic Accuracy of DiaSorin Liaison SARS-CoV-2 Antigen Immunoassay [0.03%]
DiaSorin LIAISON SARS-CoV-2抗原免疫检测试剂诊断准确性系统评价研究
Giuseppe Lippi,Brandon M Henry,Mario Plebani et al.
Giuseppe Lippi et al.
Background: Quantification of SARS-CoV-2 antigens by means of rapid, high-throughput and fully-automated techniques has been proposed as a feasible alternative to overcome the current shortage of resources for routine mol...
Review
EJIFCC. 2022 Aug 8;33(2):94-104. DOI: 2022